1

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

TUCSON, AZ 85719			_X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State) (Zip)	Table I - Non-Deriva	Table I - Non-Derivative Securities Beneficially Owned				
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock	2,000	D	Â			
Common Stock	21,890	Ι	Coronado Venture Fund IV, L.P. (1)			

C/O IMARX THERAPEUTICS, INC., 1635 EAST 18TH

(First)

(Print or Type Responses)

Person *

(Last)

1. Name and Address of Reporting

STRICKLAND JAMES M

IMARX THERAPEUTICS INC

Form 3/A

(Middle)

STREET (Street)

SECURITIES

Statement

(Month/Day/Year) 07/25/2007

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

July 30, 2007 UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 3 Washington, D.C. 20549

Edgar Filing: IMARX THERAPEUTICS INC - Form 3/A

OMB APPROVAL

OMB 3235-0104 Number: January 31, Expires: 2005 Estimated average burden hours per response... 0.5

Person(s) to Issuer (Check all applicable) 10% Owner

X Director Officer _ Other (give title below) (specify below)

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

4. Relationship of Reporting

6. Individual or Joint/Group

Filing(Check Applicable Line)

5. If Amendment, Date Original

Filed(Month/Day/Year)

07/25/2007

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

> Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

SEC 1473 (7-02)

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

IMARX THERAPEUTICS INC [IMRX]

1. Title of Derivative Security (Instr. 4)	2. Date Exer Expiration D (Month/Day/Year) Date Exercisable		3. Title and A Securities Un Derivative Se (Instr. 4) Title	derlying	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	(2)	08/02/2014	Common Stock	11,000	\$ 15	D	Â
Series A Preferred Stock	(<u>3)</u>	(4)	Common Stock	57,205 <u>(5)</u>	\$ <u>(5)</u>	Ι	Coronado Venture Fund IV, L.P. (1)

Edgar Filing: IMARX THERAPEUTICS INC - Form 3/A

Reporting Owners

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
STRICKLAND JAMES M C/O IMARX THERAPEUTICS, INC. 1635 EAST 18TH STREET TUCSON, AZ 85719	ÂX	Â	Â	Â	
Signatures					

James M.	07/30/2007
Strickland	0773072007
<u>**</u> Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reporting person is the managing partner of the sole general partner of Coronado Venture Fund IV, LP and may be deemed to have(1) voting and dispositive powers over the shares. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- (2) The option vests in four (4) equal installments on August 2, 2005, 2006, 2007 and 2008, and may be exercised prior to vesting, subject to certain rights of repurchase by the Issuer.
- (3) These shares of Preferred Stock will automatically convert into shares of Common Stock upon the closing of the Issuer's initial public offering.
- (4) Not applicable.
- (5) These shares of Preferred Stock will automatically convert into Common Stock upon the closing of the Issuer's initial public offering, and reflect a 2.75/2.63 conversion ratio, as adjusted to reflect a 6-for-10 and subsequent 1-for-3 reverse stock split.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.